Gut microbiome alterations in Alzheimer’s disease

N. Vogt(University of Wisconsin–Madison), Robert L. Kerby(University of Wisconsin–Madison), Kimberly A. Dill‐McFarland(University of Wisconsin–Madison), Sandra Harding(University of Wisconsin–Madison), Andrew P. Merluzzi(University of Wisconsin–Madison), Sterling C. Johnson(University of Wisconsin–Madison), Cynthia M. Carlsson(University of Wisconsin–Madison), Sanjay Asthana(University of Wisconsin–Madison), Henrik Zetterberg(Sahlgrenska University Hospital), Kaj Blennow(Sahlgrenska University Hospital), Barbara B. Bendlin(Wisconsin Alumni Research Foundation), Federico E. Rey(University of Wisconsin–Madison)
Scientific Reports
October 13, 2017
Cited by 2,091Open Access
Full Text

Abstract

Alzheimer's disease (AD) is the most common form of dementia. However, the etiopathogenesis of this devastating disease is not fully understood. Recent studies in rodents suggest that alterations in the gut microbiome may contribute to amyloid deposition, yet the microbial communities associated with AD have not been characterized in humans. Towards this end, we characterized the bacterial taxonomic composition of fecal samples from participants with and without a diagnosis of dementia due to AD. Our analyses revealed that the gut microbiome of AD participants has decreased microbial diversity and is compositionally distinct from control age- and sex-matched individuals. We identified phylum- through genus-wide differences in bacterial abundance including decreased Firmicutes, increased Bacteroidetes, and decreased Bifidobacterium in the microbiome of AD participants. Furthermore, we observed correlations between levels of differentially abundant genera and cerebrospinal fluid (CSF) biomarkers of AD. These findings add AD to the growing list of diseases associated with gut microbial alterations, as well as suggest that gut bacterial communities may be a target for therapeutic intervention.


Related Papers

No related papers found

Powered by citation graph analysis